Artificial intelligence and machine learning are rapidly reshaping the healthcare landscape. By tapping into these analytic tools, pharma can develop better targeted care solutions. With 9 out of 10 candidate therapies failing somewhere between phase I trials and regulatory approval, new drug development—which can cost nearly $2.6 billion according to some estimates—is ripe for disruption. AI and machine learning has the potential to help the industry develop more effective drugs quicker and at a lower cost.
Dr Ivan Griffin, COO & Co-Founder of BenevolentAI, will share his views on the industry and how it could develop.
Ivan is COO and a Co-Founder of BenevolentAI. He has 10 years’ experience as a venture capitalist encompassing all aspects of technology commercialization; identification of opportunities, company formation, business development, private and public equity financings and trade sales. He also helped launch Genomics England Ltd, a Company created to deliver the 100,000 Genomes Project as launched by the Prime Minister in 2013. Ivan holds a D.Phil. in Cognitive Neuroscience from the University of Oxford where he also completed a year’s post-doctoral research.